Literature DB >> 11457770

Dopamine-1 receptor stimulation attenuates the vasoconstrictive response to gut ischemia.

J A Guzman1, A E Rosado, J A Kruse.   

Abstract

The effects of fenoldopam, a dopamine-1 (DA-1) receptor agonist, were studied in two groups of anesthetized dogs before and after induction of splanchnic ischemia by way of hemorrhage. During the first portion of the experiment, both groups received fenoldopam (1.5 microg x kg(-1) x min(-1)) for 45 min followed by a 45-min washout. During the second portion, hemorrhage (10 ml/kg) was induced, followed by no intervention in group I (controls) and restarting of the fenoldopam infusion in group II. Prehemorrhage, fenoldopam increased composite portal blood flow by 33% (P < 0.01). After hemorrhage-induced splanchnic ischemia, fenoldopam restored portal vein blood flow to near baseline, maintained the splanchnic fraction of cardiac output, and attenuated the rise in gut mucosal PCO(2). DA-1 receptor stimulation increased portal blood flow and redistributed blood flow away from the serosal layer in favor of the mucosa during basal conditions and after hemorrhage, suggesting a more concentrated distribution of splanchnic DA-1 receptors within the mucosal layer vasculature. Fenoldopam maintained splanchnic blood flow during hypoperfusion and attenuated the splanchnic vasoconstrictive response to hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457770     DOI: 10.1152/jappl.2001.91.2.596

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  2 in total

1.  DR1 Activation Inhibits the Proliferation of Vascular Smooth Muscle Cells through Increasing Endogenous H2S in Diabetes.

Authors:  Yuxin Xi; Xin Wen; Yuanzhou Zhang; Lijie Jiao; Shuzhi Bai; Sa Shi; Guiquan Chang; Ren Wu; Fengqi Sun; Jinghui Hao; Hongzhu Li
Journal:  Aging Dis       Date:  2022-06-01       Impact factor: 9.968

Review 2.  Clinical review: splanchnic ischaemia.

Authors:  Stephan M Jakob
Journal:  Crit Care       Date:  2002-04-08       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.